Aeira Pte. Ltd.
Privately held: no public share price · Singapore
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | IL-4R-alphaMonoclonal antibody | Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaPrurigo Nodularis |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
CN, NMPA · Keymed Biosciences · Source ↗
CN, NMPA · Keymed Biosciences · Source ↗
28 April 2024Topline resultstapokibartPhase III PHECDA (NCT05908032) in seasonal allergic rhinitis met its primary endpoint
Keymed Biosciences Inc. · Source ↗
Financial reports
No financial reports recorded.